סרטן ערמונית גרורתי
02.02.2020
- איגודים
- אונקולוגיה
- אורולוגיה
- אלרגיה ואימונולוגיה
- טיפול נמרץ
- מומחים צעירים
- מיילדות וגינקולוגיה
- משפחה
- נוירולוגיה
- עור ומין
- המטולוגיה
- חברות
- אורואונקולוגיה
- אם ועובר
- אנדוסקופיה גינקולוגית
- גידולי מערכת העיכול
- גיל המעבר
- החברה להפרעת קשב
- החברה לכאב ראש
- הפרעות תנועה
- טיפול בכאב
- טיפול פליאטיבי
- מחלות מטבוליות
- מלנומה
- סרטן השד
- סרטן ריאות
- רדיותרפיה
- רפואת אורחות חיים
- יו"ר: ד"ר דוד סריד
- עורכת האתר: ד"ר אביבית פאר
הודעות, עדכונים וחדשות
Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer
A neoadjuvant regimen of durvalumab (Imfinzi) plus olaparib (Lynparza) induced a pathologic complete response (pCR) rate of 50% in patients with muscle-invasive bladder carcinoma (MIBC), according to findings from the phase II NEODURVARIB trial
Low-Dose Rapamycin Prevents Progression in Men With Prostate Cancer Under Active Surveillance
Low-dose rapamycin (sirolimus) may safely prevent disease progression in men with intermediate grade prostate cancer who are under active surveillance, according to a study presented here at the 2020 Clinical Immuno-Oncology Symposium
Most Patients With Cancer With Autoimmune Diseases Can Safely Receive Immunotherapy
Although patients with advanced cancer with a history of autoimmune diseases are often excluded from immunotherapy clinical trials, many can safely take immune checkpoint inhibitors, according to a study presented here at the 2020 Clinical Immuno-Oncology Symposium
Cytoreductive Nephrectomy Associated With Better Survival for mRCC Treated With Targeted Therapy or Immunotherapy
The use of cytoreductive nephrectomy (CN) was associated with a significant overall survival (OS) benefit in patients with metastatic renal cell carcinoma (mRCC) who were also treated with either targeted therapy or immune checkpoint inhibitors, according to a retrospective study
Frontline Enfortumab Vedotin Plus Pembrolizumab Shows Encouraging Data in Advanced Urothelial Cancer
Enfortumab vedotin-ejfv (Padcev) combined with pembrolizumab (Keytruda) led to an objective response rate (ORR) of 73% in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-based chemotherapy
Darolutamide Improves Survival in Nonmetastatic CRPC
Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) led to a significant improvement in overall survival (OS) compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to results from a preplanned final OS analysis of the phase III ARAMIS trial
